Advantage Alpha Capital Partners LP Acquires New Position in Krystal Biotech, Inc. $KRYS

Key Points

• Advantage Alpha Capital Partners LP has acquired a new stake in Krystal Biotech, Inc., purchasing 3,569 shares valued at approximately $643,000 during the 1st quarter.
• Institutional investors and hedge funds currently own 86.29% of Krystal Biotech's stock, indicating strong interest and confidence from large financial entities.
• Recent analysts' ratings reflect a generally positive outlook on the stock, with a consensus rating of "Buy" and an average target price of $210.75.

Advantage Alpha Capital Partners LP bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,569 shares of the company's stock, valued at approximately $643,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. bought a new position in shares of Krystal Biotech during the first quarter valued at $33,455,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Krystal Biotech in the first quarter worth about $74,000. Brooklyn Investment Group raised its stake in Krystal Biotech by 291.7% during the first quarter. Brooklyn Investment Group now owns 141 shares of the company's stock valued at $25,000 after purchasing an additional 105 shares in the last quarter. Fox Run Management L.L.C. grew its position in Krystal Biotech by 8.9% in the first quarter. Fox Run Management L.L.C. now owns 2,354 shares of the company's stock worth $424,000 after acquiring an additional 193 shares in the last quarter. Finally, E Fund Management Co. Ltd. increased its position in shares of Krystal Biotech by 16.8% during the 1st quarter. E Fund Management Co. Ltd. now owns 2,258 shares of the company's stock valued at $407,000 after purchasing an additional 324 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the sale, the insider directly owned 1,508,056 shares of the company's stock, valued at $226,208,400. This represents a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last ninety days, insiders sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is owned by corporate insiders.

Krystal Biotech Stock Down 0.6%

Krystal Biotech stock traded down $0.90 during mid-day trading on Wednesday, reaching $145.98. 37,136 shares of the company's stock were exchanged, compared to its average volume of 328,551. The company has a market cap of $4.22 billion, a P/E ratio of 29.66 and a beta of 0.70. The company has a fifty day moving average of $144.84 and a 200-day moving average of $154.39. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The company had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Equities research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KRYS has been the subject of several recent research reports. Guggenheim reduced their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Bank of America lowered their price target on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Chardan Capital reduced their price objective on Krystal Biotech from $219.00 to $216.00 and set a "buy" rating for the company in a research note on Friday, August 22nd. Citigroup reaffirmed a "neutral" rating and set a $166.00 target price (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, HC Wainwright restated a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $210.38.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).